Our approach to corporate culture is to develop and encourage a unique creativity we can leverage throughout the process of scientific discovery at KemPharm®.

Who We Are

KemPharm® is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs.

What We Do

We employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create these new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect.

KemPharm® has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.

KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition, the company has received FDA approval for Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate, as well as KP511, a prodrug of hydromorphone designed to be abuse-deterrent. KemPharm is developing KP511 in both ER and IR formulations.